Literature DB >> 8842275

Managed care and the infectious diseases specialist.

A D Tice1, T G Slama, S Berman, P Braun, J P Burke, A Cherney, P A Gross, P Harris, M Reid-Hatton, R Hoffman, P Joseph, S Lawton, R M Massanari, Z I Miller, W J Osheroff, D Poretz, M Shalowitz, B Simmons, J P Turner, B Wade, B R Nolet.   

Abstract

There is growing demand to contain health care costs and to reassess the value of medical services. The traditional hospital, academic, and research roles of the infectious disease (ID) specialist are threatened, yet there is an increasing need for expertise because of growing antimicrobial resistance and emerging pathogens. Opportunities exist to develop and expand services for the care of patients infected with human immunodeficiency virus and in infection control, epidemiology, outcomes research, outpatient intravenous therapy, and resource management. It is important for ID physicians to appreciate the principles involved in managed care and the areas in which ID services can be valuable. To be effective, physicians need to know about tools such as practice guidelines, physician profiling, outcomes monitoring, computerized information management, risk sharing, networking, and marketing, as well as related legal issues. With a positive attitude toward learning, application, and leadership, ID physicians can redefine their role and expand their services through managed care.

Entities:  

Mesh:

Year:  1996        PMID: 8842275     DOI: 10.1093/clinids/23.2.341

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  3 in total

1.  Infectious diseases training in Canada: one size does not fit all.

Authors:  B C Lee
Journal:  Can J Infect Dis       Date:  2001-03

Review 2.  Place of parenteral cephalosporins in the ambulatory setting: clinical evidence.

Authors:  D Nathwani
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 3.  Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins.

Authors:  A D Tice
Journal:  Drugs       Date:  2000       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.